TriSalus Life Sciences Inc. (TLSI) Insider Trading

Last 12 months

Insiders bought $3.61M and sold $140k on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan.

Net open-market

+$3.47M

10 buys · 9 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

6 / 5

executives and directors

Last open-market buy

May 2026

May 15, 2026

Get an email when TLSI's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 5	Bryan F. Cox Chief of Research	SoldNo plan	296	$4.39	$1k	0.2%	Form 4
Oct 5	Richard Marshak Chief Commercial Officer	SoldNo plan	325	$4.39	$1k	0.3%	Form 4
Oct 5	Jennifer Stevens Chief Regulatory Officer	SoldNo plan	316	$4.39	$1k	0.3%	Form 4
May 15	Richard Marshak Chief Commercial Officer	SoldNo plan	543	$2.67	$1k	0.4%	Form 4
May 15	Mats Wahlstrom Director	Bought	60,000	$2.53	$152k	2.1%	Form 4
May 15	Michael P Stansky Director	Bought 2 parts	610,000	$2.50 average	$1.52M	59%	Form 4
May 15	Mary T Szela CEO and President	Bought	39,682	$2.59	$103k	3.9%	Form 4
May 15	David Patience Chief Financial Officer	Bought	7,100	$2.43	$17k	2.6%	Form 4
May 15	Gary B. Gordon Director	Bought	10,000	$2.46	$25k	16%	Form 4
Mar 11 – 17	Mary T Szela CEO and President	SoldNo plan 2 parts	20,302	$3.91 average	$79k	2.6%	Form 4
Mar 11 – 16	Jodi Devlin Chief of Clinical Operations	SoldNo plan 3 parts	3,207	$4.11 average	$13k	3.2%	Form 4
Mar 11 – 16	Bryan F. Cox Chief of Research	SoldNo plan 3 parts	3,184	$4.11 average	$13k	1.9%	Form 4
Mar 11 – 16	Richard Marshak Chief Commercial Officer	SoldNo plan 3 parts	3,457	$4.11 average	$14k	3.0%	Form 4
Mar 11 – 16	Jennifer Stevens Chief Regulatory Officer	SoldNo plan 3 parts	3,530	$4.11 average	$15k	2.8%	Form 4
Feb 23	David Patience Chief Financial Officer	Bought	3,657	$4.10	$15k	1.4%	Form 4
Feb 23	Gary B. Gordon Director	Bought	9,756	$4.10	$40k	New	Form 4
Feb 23	William Valle Director	Bought	30,487	$4.10	$125k	New	Form 4
Feb 23	Mary T Szela CEO and President	Bought	30,487	$4.10	$125k	4.1%	Form 4
Feb 23	Michael P Stansky Director	Bought 2 parts	361,098	$4.10 average	$1.48M	58%	Form 4
May 19, 2025	Bryan F. Cox Chief of Research	SoldNo plan	4,764	$5.18	$25k	3.8%	Form 4
May 19, 2025	Jodi Devlin Chief of Clinical Operations	SoldNo plan	4,764	$5.18	$25k	8.3%	Form 4
May 19, 2025	Richard Marshak Chief Commercial Officer	SoldNo plan	6,597	$5.18	$34k	8.7%	Form 4
May 19, 2025	Jennifer Stevens Chief Regulatory Officer	SoldNo plan	8,704	$5.18	$45k	10%	Form 4
Feb 5, 2025	James Emmett Young Chief Financial Officer	Bought	6,000	$5.65	$34k	13%	Form 4
Jan 29, 2025 – Jan 30, 2025	Mary T Szela CEO AND PRESIDENT	Bought 2 parts	10,040	$5.15 average	$52k	2.3%	Form 4
Jan 27, 2025 – Jan 28, 2025	Mary T Szela CEO AND PRESIDENT	Bought 2 parts	9,542	$5.27 average	$50k	2.2%	Form 4
Jan 27, 2025 – Jan 28, 2025	Sean Murphy Chief Manuf, Strategy&Bus Dev.	Bought 2 parts	30,000	$5.24 average	$157k	5.1%	Form 4
Jan 27, 2025	James Emmett Young Chief Financial Officer	Bought	24,000	$5.40	$130k	110%	Form 4
Dec 17, 2024	Equity Ab Frankenius Large holder	Bought	62,972	$3.97	$250k	1.0%	Form 4
Dec 10, 2024	Arjun Jj Desai Director	SoldNo plan	30,000	$3.69	$111k	11%	Form 4
Nov 22, 2024	Mats Wahlstrom Director	Bought	5,000	$4.55	$23k	0.2%	Form 4
Nov 20, 2024 – Nov 21, 2024	Mats Wahlstrom Director	Bought 2 parts	10,727	$4.39 average	$47k	0.4%	Form 4

Oct 5No plan
Bryan F. Cox
Chief of Research · sold 296 at $4.39
$1k
0.2% of stake
Oct 5No plan
Richard Marshak
Chief Commercial Officer · sold 325 at $4.39
$1k
0.3% of stake
Oct 5No plan
Jennifer Stevens
Chief Regulatory Officer · sold 316 at $4.39
$1k
0.3% of stake
May 15No plan
Richard Marshak
Chief Commercial Officer · sold 543 at $2.67
$1k
0.4% of stake
May 15
Mats Wahlstrom
Director · bought 60,000 at $2.53
$152k
2.1% of stake
May 15
Michael P Stansky
Director · bought 610,000 at avg $2.50
$1.52M
59% of stake
May 15
Mary T Szela
CEO and President · bought 39,682 at $2.59
$103k
3.9% of stake
May 15
David Patience
Chief Financial Officer · bought 7,100 at $2.43
$17k
2.6% of stake
May 15
Gary B. Gordon
Director · bought 10,000 at $2.46
$25k
16% of stake
Mar 11 – 17No plan
Mary T Szela
CEO and President · sold 20,302 at avg $3.91
$79k
2.6% of stake
Mar 11 – 16No plan
Jodi Devlin
Chief of Clinical Operations · sold 3,207 at avg $4.11
$13k
3.2% of stake
Mar 11 – 16No plan
Bryan F. Cox
Chief of Research · sold 3,184 at avg $4.11
$13k
1.9% of stake
Mar 11 – 16No plan
Richard Marshak
Chief Commercial Officer · sold 3,457 at avg $4.11
$14k
3.0% of stake
Mar 11 – 16No plan
Jennifer Stevens
Chief Regulatory Officer · sold 3,530 at avg $4.11
$15k
2.8% of stake
Feb 23
David Patience
Chief Financial Officer · bought 3,657 at $4.10
$15k
1.4% of stake
Feb 23
Gary B. Gordon
Director · bought 9,756 at $4.10
$40k
New position
Feb 23
William Valle
Director · bought 30,487 at $4.10
$125k
New position
Feb 23
Mary T Szela
CEO and President · bought 30,487 at $4.10
$125k
4.1% of stake
Feb 23
Michael P Stansky
Director · bought 361,098 at avg $4.10
$1.48M
58% of stake
May 19, 2025No plan
Bryan F. Cox
Chief of Research · sold 4,764 at $5.18
$25k
3.8% of stake
May 19, 2025No plan
Jodi Devlin
Chief of Clinical Operations · sold 4,764 at $5.18
$25k
8.3% of stake
May 19, 2025No plan
Richard Marshak
Chief Commercial Officer · sold 6,597 at $5.18
$34k
8.7% of stake
May 19, 2025No plan
Jennifer Stevens
Chief Regulatory Officer · sold 8,704 at $5.18
$45k
10% of stake
Feb 5, 2025
James Emmett Young
Chief Financial Officer · bought 6,000 at $5.65
$34k
13% of stake
Jan 29, 2025 – Jan 30, 2025
Mary T Szela
CEO AND PRESIDENT · bought 10,040 at avg $5.15
$52k
2.3% of stake
Jan 27, 2025 – Jan 28, 2025
Mary T Szela
CEO AND PRESIDENT · bought 9,542 at avg $5.27
$50k
2.2% of stake
Jan 27, 2025 – Jan 28, 2025
Sean Murphy
Chief Manuf, Strategy&Bus Dev. · bought 30,000 at avg $5.24
$157k
5.1% of stake
Jan 27, 2025
James Emmett Young
Chief Financial Officer · bought 24,000 at $5.40
$130k
110% of stake
Dec 17, 2024
Equity Ab Frankenius
Large holder · bought 62,972 at $3.97
$250k
1.0% of stake
Dec 10, 2024No plan
Arjun Jj Desai
Director · sold 30,000 at $3.69
$111k
11% of stake
Nov 22, 2024
Mats Wahlstrom
Director · bought 5,000 at $4.55
$23k
0.2% of stake
Nov 20, 2024 – Nov 21, 2024
Mats Wahlstrom
Director · bought 10,727 at avg $4.39
$47k
0.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TLSI, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Surgical & Medical Instruments & Apparatus

KRMDKoru Medical Systems Inc.

SNWVSanuwave Health Inc.

CLPTClearPoint Neuro Inc.

SSIISS Innovations International, Inc.

UTMDUtah Medical Products Inc.

CTSOCytosorbents Corporation

RVPRetractable Technologies Inc.

SIShoulder Innovations, Inc.

Spot a number that looks wrong? Check it in TLSI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TLSI

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.